ID   MRCKB_HUMAN             Reviewed;        1711 AA.
AC   Q9Y5S2; A9JR72; Q2L7A5; Q86TJ1; Q9ULU5;
DT   08-NOV-2005, integrated into UniProtKB/Swiss-Prot.
DT   04-APR-2006, sequence version 2.
DT   22-JUL-2015, entry version 141.
DE   RecName: Full=Serine/threonine-protein kinase MRCK beta;
DE            EC=2.7.11.1;
DE   AltName: Full=CDC42-binding protein kinase beta;
DE            Short=CDC42BP-beta;
DE   AltName: Full=DMPK-like beta;
DE   AltName: Full=Myotonic dystrophy kinase-related CDC42-binding kinase beta;
DE            Short=MRCK beta;
DE            Short=Myotonic dystrophy protein kinase-like beta;
GN   Name=CDC42BPB {ECO:0000312|EMBL:AAD37506.1};
GN   Synonyms=KIAA1124 {ECO:0000312|EMBL:BAA86438.2};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1] {ECO:0000305, ECO:0000312|EMBL:AAD37506.1}
RP   NUCLEOTIDE SEQUENCE [MRNA], AND TISSUE SPECIFICITY.
RC   TISSUE=Brain {ECO:0000312|EMBL:AAD37506.1};
RX   PubMed=10198171; DOI=10.1006/geno.1999.5769;
RA   Moncrieff C.L., Bailey M.E., Morrison N., Johnson K.J.;
RT   "Cloning and chromosomal localization of human Cdc42-binding protein
RT   kinase beta.";
RL   Genomics 57:297-300(1999).
RN   [2] {ECO:0000312|EMBL:BAA86438.2}
RP   NUCLEOTIDE SEQUENCE [MRNA], AND VARIANT LYS-1203.
RC   TISSUE=Brain {ECO:0000312|EMBL:BAA86438.2};
RX   PubMed=10574461; DOI=10.1093/dnares/6.5.329;
RA   Hirosawa M., Nagase T., Ishikawa K., Kikuno R., Nomura N., Ohara O.;
RT   "Characterization of cDNA clones selected by the GeneMark analysis
RT   from size-fractionated cDNA libraries from human brain.";
RL   DNA Res. 6:329-336(1999).
RN   [3] {ECO:0000305}
RP   SEQUENCE REVISION.
RX   PubMed=12168954; DOI=10.1093/dnares/9.3.99;
RA   Nakajima D., Okazaki N., Yamakawa H., Kikuno R., Ohara O., Nagase T.;
RT   "Construction of expression-ready cDNA clones for KIAA genes: manual
RT   curation of 330 KIAA cDNA clones.";
RL   DNA Res. 9:99-106(2002).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT VAL-1077.
RG   NIEHS SNPs program;
RL   Submitted (JAN-2006) to the EMBL/GenBank/DDBJ databases.
RN   [5] {ECO:0000305, ECO:0000312|EMBL:AAH47871.1}
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANT LYS-1203.
RC   TISSUE=PNS {ECO:0000312|EMBL:AAH47871.1};
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1690, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P.,
RA   Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in
RT   signaling networks.";
RL   Cell 127:635-648(2006).
RN   [7]
RP   IDENTIFICATION BY MASS SPECTROMETRY, FUNCTION, AND INTERACTION WITH
RP   LURAP1 AND MYO18A.
RX   PubMed=18854160; DOI=10.1016/j.cell.2008.09.018;
RA   Tan I., Yong J., Dong J.M., Lim L., Leung T.;
RT   "A tripartite complex containing MRCK modulates lamellar actomyosin
RT   retrograde flow.";
RL   Cell 135:123-136(2008).
RN   [8]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1690, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of
RT   the kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [9]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [10]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.M800588-MCP200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [11]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1690, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [12]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [13]
RP   SUBCELLULAR LOCATION.
RX   PubMed=21240187; DOI=10.1038/emboj.2010.353;
RA   Huo L., Wen W., Wang R., Kam C., Xia J., Feng W., Zhang M.;
RT   "Cdc42-dependent formation of the ZO-1/MRCKbeta complex at the leading
RT   edge controls cell migration.";
RL   EMBO J. 30:665-678(2011).
RN   [14]
RP   FUNCTION IN PHOSPHORYLATION OF PPP1R12A AND MYL9/MLC2, AND ENZYME
RP   REGULATION.
RX   PubMed=21457715; DOI=10.1016/j.febslet.2011.03.054;
RA   Tan I., Lai J., Yong J., Li S.F., Leung T.;
RT   "Chelerythrine perturbs lamellar actomyosin filaments by selective
RT   inhibition of myotonic dystrophy kinase-related Cdc42-binding
RT   kinase.";
RL   FEBS Lett. 585:1260-1268(2011).
RN   [15]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1690 AND SER-1693, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J.,
RA   Johansen P.T., Kratchmarova I., Kassem M., Mann M., Olsen J.V.,
RA   Blagoev B.;
RT   "System-wide temporal characterization of the proteome and
RT   phosphoproteome of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [16]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-423; SER-1680; SER-1682
RP   AND SER-1686, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [17]
RP   X-RAY CRYSTALLOGRAPHY (2.15 ANGSTROMS) OF 2-417 IN COMPLEXES WITH
RP   FASUDIL AND TPCA-1, FUNCTION, SUBUNIT, AND CATALYTIC ACTIVITY.
RX   PubMed=21949762; DOI=10.1371/journal.pone.0024825;
RA   Heikkila T., Wheatley E., Crighton D., Schroder E., Boakes A.,
RA   Kaye S.J., Mezna M., Pang L., Rushbrooke M., Turnbull A., Olson M.F.;
RT   "Co-crystal structures of inhibitors with MRCKbeta, a key regulator of
RT   tumor cell invasion.";
RL   PLoS ONE 6:E24825-E24825(2011).
RN   [18]
RP   VARIANTS [LARGE SCALE ANALYSIS] GLU-500; GLN-555; GLN-671; TRP-876;
RP   LYS-1315 AND TYR-1633.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Serine/threonine-protein kinase which is an important
CC       downstream effector of CDC42 and plays a role in the regulation of
CC       cytoskeleton reorganization and cell migration. Regulates actin
CC       cytoskeletal reorganization via phosphorylation of PPP1R12C and
CC       MYL9/MLC2. In concert with MYO18A and LURAP1, is involved in
CC       modulating lamellar actomyosin retrograde flow that is crucial to
CC       cell protrusion and migration. Phosphorylates PPP1R12A.
CC       {ECO:0000269|PubMed:18854160, ECO:0000269|PubMed:21457715,
CC       ECO:0000269|PubMed:21949762}.
CC   -!- CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.
CC       {ECO:0000250|UniProtKB:Q5VT25, ECO:0000269|PubMed:21949762}.
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420;
CC         Evidence={ECO:0000250|UniProtKB:Q5VT25};
CC   -!- ENZYME REGULATION: Maintained in an inactive, closed conformation
CC       by an interaction between the kinase domain and the negative
CC       autoregulatory C-terminal coiled-coil region. Agonist binding to
CC       the phorbol ester binding site disrupts this, releasing the kinase
CC       domain to allow N-terminus-mediated dimerization and kinase
CC       activation by transautophosphorylation (By similarity). Inhibited
CC       by chelerythrine chloride. {ECO:0000250,
CC       ECO:0000269|PubMed:21457715}.
CC   -!- SUBUNIT: Homodimer and homotetramer via the coiled coil regions.
CC       Interacts tightly with GTP-bound but not GDP-bound CDC42.
CC       Interacts with TJP1, when in the presence of catalytically active
CC       CDC42 (By similarity). Forms a tripartite complex with MYO18A and
CC       LURAP1 with the latter acting as an adapter connecting CDC42BPB
CC       and MYO18A. LURAP1 binding results in activation of CDC42BPB by
CC       abolition of its negative autoregulation. {ECO:0000250,
CC       ECO:0000269|PubMed:18854160, ECO:0000269|PubMed:21949762}.
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000250}. Cell membrane
CC       {ECO:0000269|PubMed:21240187}; Peripheral membrane protein
CC       {ECO:0000269|PubMed:21240187}; Cytoplasmic side
CC       {ECO:0000269|PubMed:21240187}. Cell junction
CC       {ECO:0000269|PubMed:21240187}. Note=Displays a dispersed punctate
CC       distribution and concentrates along the cell periphery, especially
CC       at the leading edge and cell-cell junction. This concentration is
CC       PH-domain dependent (By similarity). Detected at the leading edge
CC       of migrating cells. Localization at the leading edge of migrating
CC       cells requires interaction with catalytically active CDC42.
CC       {ECO:0000250}.
CC   -!- TISSUE SPECIFICITY: Expressed in all tissues examined, with high
CC       levels in heart, brain, placenta and lung.
CC       {ECO:0000269|PubMed:10198171}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. AGC Ser/Thr
CC       protein kinase family. DMPK subfamily. {ECO:0000305}.
CC   -!- SIMILARITY: Contains 1 AGC-kinase C-terminal domain.
CC       {ECO:0000305}.
CC   -!- SIMILARITY: Contains 1 CNH domain. {ECO:0000255|PROSITE-
CC       ProRule:PRU00795}.
CC   -!- SIMILARITY: Contains 1 CRIB domain. {ECO:0000255|PROSITE-
CC       ProRule:PRU00057}.
CC   -!- SIMILARITY: Contains 1 PH domain. {ECO:0000255|PROSITE-
CC       ProRule:PRU00145}.
CC   -!- SIMILARITY: Contains 1 phorbol-ester/DAG-type zinc finger.
CC       {ECO:0000255|PROSITE-ProRule:PRU00226}.
CC   -!- SIMILARITY: Contains 1 protein kinase domain.
CC       {ECO:0000255|PROSITE-ProRule:PRU00159}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAH47871.1; Type=Miscellaneous discrepancy; Note=Contaminating sequence. Potential poly-A sequence.; Evidence={ECO:0000305};
CC       Sequence=BAA86438.2; Type=Erroneous initiation; Note=Translation N-terminally shortened.; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=NIEHS-SNPs;
CC       URL="http://egp.gs.washington.edu/data/cdc42bpb/";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF128625; AAD37506.1; -; mRNA.
DR   EMBL; AB032950; BAA86438.2; ALT_INIT; mRNA.
DR   EMBL; DQ355971; ABC67469.1; -; Genomic_DNA.
DR   EMBL; BC047871; AAH47871.1; ALT_SEQ; mRNA.
DR   EMBL; BC155541; AAI55542.1; -; mRNA.
DR   CCDS; CCDS9978.1; -.
DR   RefSeq; NP_006026.3; NM_006035.3.
DR   UniGene; Hs.654634; -.
DR   PDB; 3QFV; X-ray; 2.65 A; A/B=1-415.
DR   PDB; 3TKU; X-ray; 2.15 A; A/B=2-417.
DR   PDB; 4UAK; X-ray; 1.73 A; A=2-417.
DR   PDB; 4UAL; X-ray; 1.71 A; A=2-417.
DR   PDBsum; 3QFV; -.
DR   PDBsum; 3TKU; -.
DR   PDBsum; 4UAK; -.
DR   PDBsum; 4UAL; -.
DR   ProteinModelPortal; Q9Y5S2; -.
DR   SMR; Q9Y5S2; 2-417.
DR   BioGrid; 114947; 12.
DR   IntAct; Q9Y5S2; 9.
DR   MINT; MINT-5005780; -.
DR   STRING; 9606.ENSP00000355237; -.
DR   BindingDB; Q9Y5S2; -.
DR   ChEMBL; CHEMBL5052; -.
DR   GuidetoPHARMACOLOGY; 1508; -.
DR   PhosphoSite; Q9Y5S2; -.
DR   BioMuta; CDC42BPB; -.
DR   DMDM; 92090617; -.
DR   MaxQB; Q9Y5S2; -.
DR   PaxDb; Q9Y5S2; -.
DR   PRIDE; Q9Y5S2; -.
DR   DNASU; 9578; -.
DR   Ensembl; ENST00000361246; ENSP00000355237; ENSG00000198752.
DR   GeneID; 9578; -.
DR   KEGG; hsa:9578; -.
DR   UCSC; uc001ymi.1; human.
DR   CTD; 9578; -.
DR   GeneCards; GC14M103398; -.
DR   H-InvDB; HIX0011995; -.
DR   H-InvDB; HIX0011996; -.
DR   HGNC; HGNC:1738; CDC42BPB.
DR   HPA; HPA022821; -.
DR   MIM; 614062; gene.
DR   neXtProt; NX_Q9Y5S2; -.
DR   PharmGKB; PA26268; -.
DR   eggNOG; COG0515; -.
DR   GeneTree; ENSGT00760000118994; -.
DR   HOGENOM; HOG000294133; -.
DR   HOVERGEN; HBG055933; -.
DR   InParanoid; Q9Y5S2; -.
DR   KO; K16307; -.
DR   OMA; SCFSDRG; -.
DR   OrthoDB; EOG7BW0N7; -.
DR   PhylomeDB; Q9Y5S2; -.
DR   TreeFam; TF313551; -.
DR   SignaLink; Q9Y5S2; -.
DR   ChiTaRS; CDC42BPB; human.
DR   GenomeRNAi; 9578; -.
DR   NextBio; 35465240; -.
DR   PRO; PR:Q9Y5S2; -.
DR   Proteomes; UP000005640; Chromosome 14.
DR   Bgee; Q9Y5S2; -.
DR   CleanEx; HS_CDC42BPB; -.
DR   ExpressionAtlas; Q9Y5S2; baseline and differential.
DR   Genevisible; Q9Y5S2; HS.
DR   GO; GO:0042641; C:actomyosin; IDA:UniProtKB.
DR   GO; GO:0031252; C:cell leading edge; ISS:UniProtKB.
DR   GO; GO:0005911; C:cell-cell junction; ISS:UniProtKB.
DR   GO; GO:0005737; C:cytoplasm; IEA:UniProtKB-SubCell.
DR   GO; GO:0005856; C:cytoskeleton; TAS:ProtInc.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0005524; F:ATP binding; ISS:UniProtKB.
DR   GO; GO:0000287; F:magnesium ion binding; ISS:UniProtKB.
DR   GO; GO:0004672; F:protein kinase activity; IDA:UniProtKB.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; ISS:UniProtKB.
DR   GO; GO:0031532; P:actin cytoskeleton reorganization; ISS:UniProtKB.
DR   GO; GO:0031032; P:actomyosin structure organization; IMP:UniProtKB.
DR   GO; GO:0016477; P:cell migration; IMP:UniProtKB.
DR   GO; GO:0007010; P:cytoskeleton organization; TAS:ProtInc.
DR   GO; GO:0007163; P:establishment or maintenance of cell polarity; TAS:ProtInc.
DR   GO; GO:0035556; P:intracellular signal transduction; IEA:InterPro.
DR   GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB.
DR   GO; GO:0007165; P:signal transduction; TAS:ProtInc.
DR   InterPro; IPR000961; AGC-kinase_C.
DR   InterPro; IPR001180; Citron.
DR   InterPro; IPR000095; CRIB_dom.
DR   InterPro; IPR020454; DAG/PE-bd.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR014930; Myotonic_dystrophy_kinase_coil.
DR   InterPro; IPR002219; PE/DAG-bd.
DR   InterPro; IPR001849; PH_domain.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR002290; Ser/Thr_dual-sp_kinase.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   Pfam; PF00130; C1_1; 1.
DR   Pfam; PF00780; CNH; 1.
DR   Pfam; PF08826; DMPK_coil; 1.
DR   Pfam; PF00069; Pkinase; 1.
DR   PRINTS; PR00008; DAGPEDOMAIN.
DR   ProDom; PD011252; Myotonic_dystrophy_kinase_coil; 1.
DR   SMART; SM00109; C1; 1.
DR   SMART; SM00036; CNH; 1.
DR   SMART; SM00285; PBD; 1.
DR   SMART; SM00233; PH; 1.
DR   SMART; SM00133; S_TK_X; 1.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS51285; AGC_KINASE_CTER; 1.
DR   PROSITE; PS50219; CNH; 1.
DR   PROSITE; PS50108; CRIB; 1.
DR   PROSITE; PS50003; PH_DOMAIN; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
DR   PROSITE; PS00479; ZF_DAG_PE_1; 1.
DR   PROSITE; PS50081; ZF_DAG_PE_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; ATP-binding; Cell junction; Cell membrane; Coiled coil;
KW   Complete proteome; Cytoplasm; Kinase; Magnesium; Membrane;
KW   Metal-binding; Nucleotide-binding; Phosphoprotein; Polymorphism;
KW   Reference proteome; Serine/threonine-protein kinase; Transferase;
KW   Zinc; Zinc-finger.
FT   CHAIN         1   1711       Serine/threonine-protein kinase MRCK
FT                                beta.
FT                                /FTId=PRO_0000086394.
FT   DOMAIN       76    342       Protein kinase.
FT                                {ECO:0000250|UniProtKB:Q5VT25,
FT                                ECO:0000255|PROSITE-ProRule:PRU00159}.
FT   DOMAIN      343    413       AGC-kinase C-terminal.
FT   DOMAIN     1095   1214       PH. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00145}.
FT   DOMAIN     1240   1513       CNH. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00795}.
FT   DOMAIN     1583   1596       CRIB. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00057}.
FT   NP_BIND      82     90       ATP. {ECO:0000250|UniProtKB:P54265,
FT                                ECO:0000255|PROSITE-ProRule:PRU00159}.
FT   ZN_FING    1025   1075       Phorbol-ester/DAG-type.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00226}.
FT   COILED      431    815       {ECO:0000255}.
FT   COILED      878    939       {ECO:0000255}.
FT   ACT_SITE    200    200       Proton acceptor.
FT                                {ECO:0000250|UniProtKB:P54265,
FT                                ECO:0000255|PROSITE-ProRule:PRU00159,
FT                                ECO:0000255|PROSITE-ProRule:PRU10027}.
FT   BINDING     105    105       ATP. {ECO:0000250|UniProtKB:Q5VT25,
FT                                ECO:0000255|PROSITE-ProRule:PRU00159}.
FT   MOD_RES     221    221       Phosphoserine; by autocatalysis.
FT                                {ECO:0000250}.
FT   MOD_RES     233    233       Phosphoserine; by autocatalysis.
FT                                {ECO:0000250}.
FT   MOD_RES     239    239       Phosphothreonine; by autocatalysis.
FT                                {ECO:0000250}.
FT   MOD_RES     423    423       Phosphothreonine.
FT                                {ECO:0000269|PubMed:24275569}.
FT   MOD_RES     954    954       Phosphotyrosine.
FT                                {ECO:0000250|UniProtKB:Q7TT50}.
FT   MOD_RES    1680   1680       Phosphoserine.
FT                                {ECO:0000269|PubMed:24275569}.
FT   MOD_RES    1682   1682       Phosphoserine.
FT                                {ECO:0000269|PubMed:24275569}.
FT   MOD_RES    1686   1686       Phosphoserine.
FT                                {ECO:0000269|PubMed:24275569}.
FT   MOD_RES    1690   1690       Phosphoserine.
FT                                {ECO:0000269|PubMed:17081983,
FT                                ECO:0000269|PubMed:18691976,
FT                                ECO:0000269|PubMed:20068231,
FT                                ECO:0000269|PubMed:21406692}.
FT   MOD_RES    1693   1693       Phosphoserine.
FT                                {ECO:0000269|PubMed:21406692}.
FT   VARIANT     500    500       K -> E (in a breast infiltrating ductal
FT                                carcinoma sample; somatic mutation).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_040834.
FT   VARIANT     555    555       R -> Q (in dbSNP:rs36001612).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_040835.
FT   VARIANT     671    671       R -> Q (in dbSNP:rs55948035).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_040836.
FT   VARIANT     876    876       R -> W (in a colorectal adenocarcinoma
FT                                sample; somatic mutation).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_040837.
FT   VARIANT    1077   1077       I -> V (in dbSNP:rs34822377).
FT                                {ECO:0000269|Ref.4}.
FT                                /FTId=VAR_025847.
FT   VARIANT    1203   1203       R -> K (in dbSNP:rs146298297).
FT                                {ECO:0000269|PubMed:10574461,
FT                                ECO:0000269|PubMed:15489334}.
FT                                /FTId=VAR_070886.
FT   VARIANT    1315   1315       E -> K (in a lung large cell carcinoma
FT                                sample; somatic mutation).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_040838.
FT   VARIANT    1633   1633       S -> Y (in dbSNP:rs56412851).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_040839.
FT   CONFLICT   1017   1017       A -> V (in Ref. 1; AAD37506).
FT                                {ECO:0000305}.
FT   CONFLICT   1123   1123       D -> E (in Ref. 1; AAD37506).
FT                                {ECO:0000305}.
FT   HELIX         3     20       {ECO:0000244|PDB:4UAL}.
FT   STRAND       21     23       {ECO:0000244|PDB:3QFV}.
FT   HELIX        27     41       {ECO:0000244|PDB:4UAL}.
FT   HELIX        44     47       {ECO:0000244|PDB:4UAL}.
FT   HELIX        50     69       {ECO:0000244|PDB:4UAL}.
FT   HELIX        73     75       {ECO:0000244|PDB:4UAL}.
FT   STRAND       76     83       {ECO:0000244|PDB:4UAL}.
FT   STRAND       86     95       {ECO:0000244|PDB:4UAL}.
FT   STRAND      101    108       {ECO:0000244|PDB:4UAL}.
FT   HELIX       109    114       {ECO:0000244|PDB:4UAL}.
FT   TURN        115    118       {ECO:0000244|PDB:4UAL}.
FT   HELIX       121    130       {ECO:0000244|PDB:4UAL}.
FT   TURN        133    135       {ECO:0000244|PDB:4UAL}.
FT   STRAND      139    144       {ECO:0000244|PDB:4UAL}.
FT   STRAND      146    153       {ECO:0000244|PDB:4UAL}.
FT   HELIX       161    167       {ECO:0000244|PDB:4UAL}.
FT   TURN        168    170       {ECO:0000244|PDB:4UAL}.
FT   HELIX       174    193       {ECO:0000244|PDB:4UAL}.
FT   HELIX       203    205       {ECO:0000244|PDB:4UAL}.
FT   STRAND      206    208       {ECO:0000244|PDB:4UAL}.
FT   STRAND      214    216       {ECO:0000244|PDB:4UAL}.
FT   STRAND      227    229       {ECO:0000244|PDB:3QFV}.
FT   STRAND      231    235       {ECO:0000244|PDB:3TKU}.
FT   HELIX       240    242       {ECO:0000244|PDB:4UAL}.
FT   HELIX       245    253       {ECO:0000244|PDB:4UAL}.
FT   STRAND      255    258       {ECO:0000244|PDB:3TKU}.
FT   HELIX       261    276       {ECO:0000244|PDB:4UAL}.
FT   HELIX       286    294       {ECO:0000244|PDB:4UAL}.
FT   HELIX       296    299       {ECO:0000244|PDB:4UAL}.
FT   HELIX       311    318       {ECO:0000244|PDB:4UAL}.
FT   HELIX       324    326       {ECO:0000244|PDB:4UAL}.
FT   STRAND      330    333       {ECO:0000244|PDB:4UAL}.
FT   HELIX       334    337       {ECO:0000244|PDB:4UAL}.
FT   HELIX       340    342       {ECO:0000244|PDB:4UAL}.
FT   TURN        347    349       {ECO:0000244|PDB:4UAL}.
FT   HELIX       350    352       {ECO:0000244|PDB:4UAL}.
FT   STRAND      362    365       {ECO:0000244|PDB:4UAK}.
FT   HELIX       396    398       {ECO:0000244|PDB:4UAL}.
FT   STRAND      403    406       {ECO:0000244|PDB:3QFV}.
FT   STRAND      408    412       {ECO:0000244|PDB:3QFV}.
SQ   SEQUENCE   1711 AA;  194315 MW;  041A009E0273ABE0 CRC64;
     MSAKVRLKKL EQLLLDGPWR NESALSVETL LDVLVCLYTE CSHSALRRDK YVAEFLEWAK
     PFTQLVKEMQ LHREDFEIIK VIGRGAFGEV AVVKMKNTER IYAMKILNKW EMLKRAETAC
     FREERDVLVN GDCQWITALH YAFQDENHLY LVMDYYVGGD LLTLLSKFED KLPEDMARFY
     IGEMVLAIDS IHQLHYVHRD IKPDNVLLDV NGHIRLADFG SCLKMNDDGT VQSSVAVGTP
     DYISPEILQA MEDGMGKYGP ECDWWSLGVC MYEMLYGETP FYAESLVETY GKIMNHEERF
     QFPSHVTDVS EEAKDLIQRL ICSRERRLGQ NGIEDFKKHA FFEGLNWENI RNLEAPYIPD
     VSSPSDTSNF DVDDDVLRNT EILPPGSHTG FSGLHLPFIG FTFTTESCFS DRGSLKSIMQ
     SNTLTKDEDV QRDLEHSLQM EAYERRIRRL EQEKLELSRK LQESTQTVQS LHGSSRALSN
     SNRDKEIKKL NEEIERLKNK IADSNRLERQ LEDTVALRQE REDSTQRLRG LEKQHRVVRQ
     EKEELHKQLV EASERLKSQA KELKDAHQQR KLALQEFSEL NERMAELRAQ KQKVSRQLRD
     KEEEMEVATQ KVDAMRQEMR RAEKLRKELE AQLDDAVAEA SKERKLREHS ENFCKQMESE
     LEALKVKQGG RGAGATLEHQ QEISKIKSEL EKKVLFYEEE LVRREASHVL EVKNVKKEVH
     DSESHQLALQ KEILMLKDKL EKSKRERHNE MEEAVGTIKD KYERERAMLF DENKKLTAEN
     EKLCSFVDKL TAQNRQLEDE LQDLAAKKES VAHWEAQIAE IIQWVSDEKD ARGYLQALAS
     KMTEELEALR SSSLGSRTLD PLWKVRRSQK LDMSARLELQ SALEAEIRAK QLVQEELRKV
     KDANLTLESK LKDSEAKNRE LLEEMEILKK KMEEKFRADT GLKLPDFQDS IFEYFNTAPL
     AHDLTFRTSS ASEQETQAPK PEASPSMSVA ASEQQEDMAR PPQRPSAVPL PTTQALALAG
     PKPKAHQFSI KSFSSPTQCS HCTSLMVGLI RQGYACEVCS FACHVSCKDG APQVCPIPPE
     QSKRPLGVDV QRGIGTAYKG HVKVPKPTGV KKGWQRAYAV VCDCKLFLYD LPEGKSTQPG
     VIASQVLDLR DDEFSVSSVL ASDVIHATRR DIPCIFRVTA SLLGAPSKTS SLLILTENEN
     EKRKWVGILE GLQSILHKNR LRNQVVHVPL EAYDSSLPLI KAILTAAIVD ADRIAVGLEE
     GLYVIEVTRD VIVRAADCKK VHQIELAPRE KIVILLCGRN HHVHLYPWSS LDGAEGSFDI
     KLPETKGCQL MATATLKRNS GTCLFVAVKR LILCYEIQRT KPFHRKFNEI VAPGSVQCLA
     VLRDRLCVGY PSGFCLLSIQ GDGQPLNLVN PNDPSLAFLS QQSFDALCAV ELESEEYLLC
     FSHMGLYVDP QGRRARAQEL MWPAAPVACS CSPTHVTVYS EYGVDVFDVR TMEWVQTIGL
     RRIRPLNSEG TLNLLNCEPP RLIYFKSKFS GAVLNVPDTS DNSKKQMLRT RSKRRFVFKV
     PEEERLQQRR EMLRDPELRS KMISNPTNFN HVAHMGPGDG MQVLMDLPLS AVPPSQEERP
     GPAPTNLARQ PPSRNKPYIS WPSSGGSEPS VTVPLRSMSD PDQDFDKEPD SDSTKHSTPS
     NSSNPSGPPS PNSPHRSQLP LEGLEQPACD T
//
